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Abstract
Background: Previous studies reported that nephrotic syndrome is associated with ulcerative colitis (UC) patients
treated with mesalazine. Dysplasia associated with UC often develops into colorectal carcinoma.
Case presentation: A 17-year-old man was referred to our hospital, complaining of diarrhea and bloody stool.
Total colonoscopy (TC) was performed and total-type UC was diagnosed. After treatment with mesalazine for
5 years, a low-grade dysplasia (LGD) was detected in the rectum by histological analysis of a biopsy sample. One
month later, he complained of dyspnea and edema. He was diagnosed with nephrotic syndrome and administered
steroid and immunosuppressant treatment: cyclosporine and mizoribine. Eight years after LGD was detected, he
complained of abdominal distension and pain. Stenosis of the upper rectum by an advanced rectal carcinoma was
detected. Abdominal computed tomography showed a rectal tumor with multiple lymph node metastases.
Transverse colostomy was performed surgically, followed by two cycles of modified FOLFOX6 and panitumumab.
He safely underwent a total proctocolectomy with a stapled ileal pouch anal-canal anastomosis, total mesorectal
and bilateral pelvic lymph node dissection, and temporary loop ileostomy. Metastases were observed in 25 lymph
nodes microscopically. The pathological stage of rectal carcinoma was pT3N2bM1a. After one cycle of modified
FOLFOX6 postoperatively, he was discharged from the hospital.
Conclusions: A patient with UC associated with nephrotic syndrome was treated with mesalazine. LGD developed
into an advanced rectal carcinoma after an 8-year interval. The use of immunosuppressants for the treatment of
nephrotic syndrome might affect the development of rectal carcinoma.
Trial registration: Trial registration: Case report registration #1626
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Background
Long-standing ulcerative colitis (UC) patients are often as-
sociated with colorectal dysplasia or colorectal carcinoma
(CRC). Patients with UC have a 2.4-fold increased overall
risk of CRC [1]. The cumulative probability of UC patients
developing CRC is 2 % by 10 years, 8 % by 20 years, and
18 % by 30 years, according to a meta-analysis [2].
Riddell described two categories of dysplasia associated
with UC, indefinite and positive dysplasia [3]. The indefin-
ite category includes the subcategories: probably negative
(probably inflammatory), unknown, and probably positive
(probably dysplastic). The positive category includes low-
grade dysplasia (LGD) and high-grade dysplasia (HGD). It
is therefore important to conduct surveillance colonos-
copy to detect dysplasia before CRC develops [4].
Previous studies reported that UC patients treated
with mesalazine were associated with nephrotic syn-
drome (NS) [5]. The relationship between mesalazine
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and NS is unclear. Steroids and immunosuppressants
used for the treatment of NS might accelerate the ad-
vancement of dysplasia to colitic carcinoma.
The standard surgical procedure for patients with UC
is restorative proctocolectomy with construction of an
ileal pouch. Colectomy for UC patients with advanced
carcinoma requires sufficient lymph nodes resections.
Case presentation
A 17-year-old man complained of diarrhea and bloody
stools and was referred to our hospital in 2000. His fam-
ily had no particular disease. He was diagnosed with
total-type UC by total colonoscopy (TC). The patient
had no primary sclerosing cholangitis. Mesalazine at
2250 mg/day was prescribed. In June 2005, he under-
went TC. Immunohistochemical analysis of a rectum bi-
opsy showed LGD with an overexpression of p53
protein. The following month he complained dyspnea
and edema of the whole body and he gained 4 kg in
weight. He was consulted by a nephrology physician. La-
boratory data showed total protein of 4.5 g/dl, albumin
of 1.4 g/dl, total cholesterol of 352 mg/dl, creatinine of
1.7 mg/dl, and blood urea nitrogen of 43 mg/dl in the
serum. His urine showed proteinuria 3.6 g/day. He was
diagnosed with NS according to the criteria. Biopsy of
the kidney demonstrated a minimal change in NS histo-
logically. Prednisolone at 35 mg/day was initiated. Cyclo-
sporine at 250 mg/day and mizoribine at 150 mg/day
were added because of steroid resistance. His symptoms
disappeared after 3 months of medication.
Mesalazine had not been administered to the patient
since 2008. Prednisolone was tapered to 12.5 mg. TC
was performed in 2013 and a stenotic lesion was de-
tected in the rectum. Biopsy of the rectum showed LGD
histologically.
In July 2014, he complained of abdominal distension.
Abdominal X-ray showed distension of the colon and an
abdominal computed tomography (CT) scan showed a
rectal tumor associated with swellings of multiple ab-
dominal lymph nodes. He was admitted to our hospital.
Laboratory data at admission is shown in Table 1.
Serum carcinoembryonic antigen (CEA) and carbohy-
drate antigen 19-9 (CA19-9) levels were markedly ele-
vated. Urinalysis did not show occult blood, proteinuria,
and glycosuria. TC showed a round shaped elevated lesion
in the rectum with an ulcer on top (Fig. 1). A colonoscope
was passed through the stenosis site and inflammation of
the colorectal mucosa was mildly active. Biopsy of the rec-
tal tumor showed well-differentiated adenocarcinoma with
mucin production. Overexpression of p53 protein was ob-
served immunohistochemically. Magnetic resonance im-
aging (MRI) showed multiple swellings in the rectal
mesentery lymph nodes and lateral pelvic lymph nodes.
Transverse colostomy was performed under general
anesthesia. As KRAS gene mutation was not detected in
the biopsy specimen, the patient received a total of two
cycles of modified FOLFOX6 and panitumumab [6] over
2 months as neoadjuvant chemotherapy. Adverse effects
of chemotherapy were peripheral neuropathy (grade 1)
and skin rash in the face (grade 1). Repeated CT scan
and MRI did not show shrinkage of the tumor indicating
stable disease. Five weeks after the completion of
Table 1 Laboratory data at admission
Hemoglobin 14.4 mg/dl
White blood cell 12,300/m3





Total bilirubin 0.85 mg/dl
BUN 21.0 mg/dl
Creatinine 0.6 mg/dl
Total protein 6.1 g/dl
Albumin 3.94 g/dl
CRP 0.19 mg/dl
CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, AST aspartate
transaminase, ALT alanine aminotransferase, BUN blood urea nitrogen,
CRP C-reactive protein
Fig. 1 Endoscopic view of the rectal mucosa. Rectal mucosa with LGD in 2011 (left). Elevated and irregular rectal mucosa with LGD in 2013
(center). Rectal carcinoma in 2014 (right). LGD low-grade dysplasia
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chemotherapy, the patient underwent a total proctoco-
lectomy with a stapled ileal pouch anal-canal anasto-
mosis, total mesorectal and bilateral pelvic lymph node
dissection, and temporary loop ileostomy. The patient
fared well in the postoperative course.
The resected specimen showed an irregular shaped,
round, elevated mass that was 3 cm in diameter at the rec-
tum (Fig. 2). Background colorectal mucosa was flat with
mild inflammation confirming UC. Histological examin-
ation of the specimen revealed mucinous adenocarcinoma
with well and moderately differentiated adenocarcinoma.
Over expression of p53 protein was observed immunohis-
tochemically (Fig. 3). Metastases were observed in 25
lymph nodes including the mesorectal and bilateral pelvic
lymph nodes. Colorectal mucosa showed active UC with
cryptitis and crypt abscess histologically. The patho-
logical stage of the carcinoma was pT3N2bM1a, stage
IV, according to the TNM classification of UICC, 7th
edition [7].
The patient was discharged from the hospital after re-
ceiving 1 cycle of modified FOLFOX6. He received add-
itional 7 cycles of modified FOLFOX6 in 4 months at the
outpatient unit. Adverse effects of postoperative chemo-
therapy were peripheral neuropathy (grade 2). The patient
is currently alive without evidence of recurrence of the
carcinoma 12 months after colectomy.
We report a case of an UC patient where disease was
associated with advanced rectal carcinoma. UC was as-
sociated with NS after treatment of UC with mesalazine
for 5 years. Firwana et al. reported a case of NS after
mesalazine treatment for Crohn’s disease [5]. He also
reviewed six case reports of NS after the treatment of
UC with 5-amino-salacylic acid derivatives. All six pa-
tients were given steroids and improved. However, the
relationship between mesalazine and NS is currently
unclear.
Kiran et al. reported that carcinoma was present in
29 % of UC patients with preoperative HGD compared
with 3 % in those with LGD [8]. Thus, the risk of carcin-
oma in UC patients with HGD is substantial. In the
current case, the patient showed advanced rectal carcinoma
8 years after LGD was detected by surveillance colonos-
copy. He received steroids and immunosuppressants for
the treatment of NS. However, these reagents might
accelerate the progression of rectal carcinoma from
dysplasia.
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Fig. 3 Middle power microphotograph of resected rectal carcinoma. Well-differentiated adenocarcinoma (a) and p53-positive staining are shown
immunohistochemically (b). Moderately differentiated adenocarcinoma with mucinous carcinoma (c) and p53-positive staining are shown
immunohistochemically (d)
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The standard surgical procedure for patients with UC
is restorative proctocolectomy with construction of an
ileal pouch. Colectomy for UC patients with carcinoma
requires sufficient lymph nodes resections [9]. In this
case, 25 metastatic lymph nodes including the pelvic lat-
eral lymph nodes were resected surgically. It is very rare
that so many metastatic lymph nodes were detected in
resectable sporadic or colitic carcinoma cases without
distal organ metastases. This patient was under im-
munosuppressive conditions induced by the steroid and
immunosuppressant treatment for NS. The possibility
exists that this immunosuppressive condition was pre-
cipitated the aggressive lymph node metastases.
Advanced carcinoma affects the lifespan of UC pa-
tients. In a study conducted in Japan, Watanabe et al re-
ported that patients with CRC-associated UC showed
poorer survival rates than those with sporadic CRC in
the advanced stages, while no difference was observed in
the early stages [10]. It is important to detect dysplasia
and carcinoma at an early stage by surveillance. LGD
with an overexpression of p53 protein was detected in
this patient by surveillance colonoscopy. p53 mutations
have been shown to occur at an earlier phase in the pro-
gression of UC-associated neoplasia [11]. It had already
developed to an advanced carcinoma when he under-
went the follow-up colonoscopy. This is a rare case, and
there are still problems concerning the method of sur-
veillance and follow-up colonoscopy.
Conclusions
A patient with UC treated with mesalazine developed as-
sociated NS. Although similar cases have been reported,
a relationship between mesalazine and NS is not evident.
In this case, LGD detected by surveillance colonoscopy
developed to an advanced rectal carcinoma after an 8-
year interval. The use of immunosuppressants for the
treatment of NS might affect the progression of rectal
carcinoma and aggressive lymph node metastases.
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